Please select the option that best describes you:
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
What key factors will you consider when selecting patients for this therapy?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Obinutuzumab for Lupus Nephritis
Answer from: at Community Practice
1. Insurance Coverage: Oh, easy one! Since it is not FDA-approved yet for lupus nephritis (I bet it will be though... great data so far), insurance will unlikely cover it, except for a few (like Tricare, which is sometimes easier to get off-label drugs).
I am fortunate to have the NIH Lupus Center ...
Sign in or Register to read more
Answer from: at Academic Institution
Approximately 50% of the time in my clinical practice, when prescribing Obinutuzumab, insurance companies prefer to cover Rituximab or its biosimilars instead. With the latest data from the REGENCY trial, I am now more hesitant to use Obinutuzumab due to the higher risk of infections—primarily COV...
Comments
at Uniformed Services University of the Health Sciences (USUHS)
@Jose Rubio, you are spot on! I'd add on the last ...
@Jose Rubio, you are spot on! I'd add on the last ...